Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BloodTurbine

Financiado

Fully implantable patient specific Artificial Hearts without External Power

Patient population with end-stage heart failure in the EU grows by 5M annually. Due to donor shortage, only a handful of patients ever receive cardiac transplantation. Unfortunately, this results in 250K deaths every year. Long-te... ver más

31/10/2023

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

KOC UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-10-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2020-POC: Call for proposals for ERC Proof of Concept Grant

I+D

Cerrada hace 4 años

0% 100% 100%

2 Participantes

150.00K€ | Lider

COSMEWAX

316.20K€ | Participante

Proyectos interesantes

Biventricular Epicardial Augmentation Technology A revolutionary technology platform for providing life-savin... 4M€ Cerrado

Aeson® The World’s Only Bioprosthetic Auto-regulated Artificial Hea... 12M€ Cerrado

fitsCAN Blood flow induced thrombosis and stenosis due to cannulatio... 2M€ Cerrado

ArtOfHeart The first Total Artificial Heart (TAH) that truly mimics the... 38M€ Cerrado

Contraband ContraBand: the only heart failure medical device that is pl... 4M€ Cerrado

RTI2018-096320-B-C21 BIOINGENIERIA DE CONSTRUCTOS BASADOS EN BIOMATERIALES PARA L... 182K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 26 meses Fecha Inicio: 2021-08-30
Fecha Fin: 2023-10-31

Líder del proyecto

KOC UNIVERSITY

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Patient population with end-stage heart failure in the EU grows by 5M annually. Due to donor shortage, only a handful of patients ever receive cardiac transplantation. Unfortunately, this results in 250K deaths every year. Long-term mechanical circulatory support (MCS) is a solution, but external power needs result in driveline infections and bulky systems limiting patient mobility. An innovative blood turbine device emerged from the parent ERC that can overcome these limitations. This novel turbine can drive MCS by transferring the available cardiovascular energy to the diseased site without the need of external power. The proposed passive concept (at TRL 6-7) will realize the long-sought use of ventricle assist devices (VAD) as a destination therapy. PoC project will enable the timely translation of a disruptive device to the bedside, by completing device optimization, comparative analysis and key preclinical experiments in accordance with the new MDR regulatory framework. Business development, valuation and IPR activities are also budgeted. Elimination of the bulky power systems and control units allowed three-dimensional printing of this artificial heart from biocompatible resins. This resulted a new customized VAD concept that can be precisely tailored for each individual patient needs. Furthermore, the comparatively low product cost (€1K vs. €120K) will allow access to a major untapped global market reaching 18 million people annually, as many developing countries have no access to expensive MCS systems. These intriguing business opportunities will be validated, and major commercialization tasks will be completed through a strong team of business mentors, clinicians and cardiovascular device experts. In addition to the adults with right-heart failure, the developed device will improve the post-operative quality life of children with heart defects that require staged cardiovascular surgeries. Socioeconomic impacts span both the patients and their families.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores